Small Number of Smokers Get Screened for Lung Cancer
A study by the American Cancer Society shows that lung cancer screening rates remained very low and unchanged among current and former smokers in 2015, despite recommendations that high risk groups be screened. The findings published in JAMA Oncology highlight the need to educate clinicians and those at risk about lung cancer screening.
See Also: New Model Predicts Lung Cancer Risk in Light and Never Smokers
Annual screening for lung cancer using low-dose computed tomography (LDCT) is recommended for people ages 55 to 80 with at least a 30 pack-year smoking history (calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked). The recommendation was made by the United States Preventive Services Task Force (USPSTF) in December 2013, after the National Lung Screening Trial (NLST) showed screening this high risk population could reduce lung cancer mortality 20 percent in this population.
In 2010, before the recommendation, the National Health Interview Survey (NHIS) found only 2 to 4 percent of high risk smokers received LCDT in the previous year.
To investigate further, researchers led by Ahmedin Jemal DVM, PhD, compared responses from the NHIS between 2010 and 2015, including only those who would meet the requirements for screening under the USPSTF recommendation. The team found the proportion of eligible current and former smokers who received LCDT in the past 12 months remained low and constant between the two years, from 3.3 percent in 2010 to 3.9 percent in 2015. Based on those figures, the researchers estimate that of the 6.8 million current and former smokers eligible for screening in 2015, only 262,700 received it.
Lack of knowledge among both smokers and doctors as to screening recommendations as well as access to high quality screening could be among the reasons for the low uptake in LCDT screening, according to Dr. Jemal. "Our previous study showed implementing quality screening broadly across the U.S. could prevent about 12,000 lung cancer deaths every year in the short term," the doctor noted. "But we cannot prevent those deaths until and unless we start educating eligible smokers as well as clinicians about the benefits and risks of screening, so patients can make an informed decision."
Source: American Cancer Society
Image Credit: Pixabay
Published on : Sun, 5 Feb 2017
UltraDrape is an innovative dressing designed for use during Ultrasound-Guided Peripheral Intravenous (UGPIV) that provides dual-action barrier and securement in one.
The first wireless, handheld breast ultrasound scanner with exceptional image quality Optimized with preset modes for breast, dense breast and interventional procedures that simplify workflow On-demand high-resolution images – 14 MHz, 192 elements, and...
The TE7 touch screen ultrasound system is designed to provide superior quality imaging for rapid patient-care decisions. Intuitive gesture controls and efficient focused point-of-care exams minimize the user learning curve, with no need to navigate a...
We recognize that the best chance any patient has at getting better is a clinician at their bedside with all the right answers and the confidence to act. SonoSite education and training is the industry standard – no other point-of-care ultrasound manufacturer...
Shown to improve comfort in 93% of patients who reported moderate to severe discomfort with standard compression technology2 Curved, unique design mirrors the shape of a woman’s breast to reduce pinching and apply uniform compression over the entire...